TY - JOUR
T1 - Omics-based tracking of
Pseudomonas aeruginosa persistence in "eradicated" cystic fibrosis patients.
AU - Bartell, Jennifer A
AU - Sommer, Lea M
AU - Marvig, Rasmus L
AU - Skov, Marianne
AU - Pressler, Tacjana
AU - Molin, Søren
AU - Johansen, Helle Krogh
N1 - Copyright ©ERS 2021.
PY - 2021/4
Y1 - 2021/4
N2 - Whenever
Pseudomonas aeruginosa is cultured from cystic fibrosis (CF) patient airways, the primary goal is eradication by antibiotic therapy. Success is defined by ≥6 months of negative bacterial airway cultures. However, we suspect that
P. aeruginosa persists in airways without clinical detection for long periods.Out of 298
P. aeruginosa-infected Copenhagen CF patients, we identified 80 with complete
P. aeruginosa monitoring records and measured their maximum
P. aeruginosa-free eradication periods (MEP). Isolates from 72 patients were whole-genome sequenced (n=567) and clone typed. Select isolate relatedness was examined through phylogenetic analysis and phenotypic multivariate modelling.69 (86%) patients exhibited eradication in the monitoring period (2002-2018). Sequenced isolates bridged the MEP of 42 patients, and the same clone type persisted over the MEP in 18 (43%) patients. Patients with failed eradication were on average treated more intensively with antibiotics, but this may be linked to their more severe pre-MEP infection trajectories. Of the 42 patients, 26 also had sinus surgery; the majority (n=15) showed MEPs adjacent to surgery, and only five had persisting clone types. Importantly, combined phylogenetic-phenomic evaluation suggests that persisting clone types are a result of re-emergence of the same strain rather than re-infection from the environment, and similar relatedness is exhibited by paired lower and upper airway samples and in transmission cases.In conclusion, nearly half of CF patients with supposed eradication may not truly be cleared of their original bacteria according to omics-based monitoring. This distinct cohort that is persistently infected would probably benefit from tailored antibiotic therapy.
AB - Whenever
Pseudomonas aeruginosa is cultured from cystic fibrosis (CF) patient airways, the primary goal is eradication by antibiotic therapy. Success is defined by ≥6 months of negative bacterial airway cultures. However, we suspect that
P. aeruginosa persists in airways without clinical detection for long periods.Out of 298
P. aeruginosa-infected Copenhagen CF patients, we identified 80 with complete
P. aeruginosa monitoring records and measured their maximum
P. aeruginosa-free eradication periods (MEP). Isolates from 72 patients were whole-genome sequenced (n=567) and clone typed. Select isolate relatedness was examined through phylogenetic analysis and phenotypic multivariate modelling.69 (86%) patients exhibited eradication in the monitoring period (2002-2018). Sequenced isolates bridged the MEP of 42 patients, and the same clone type persisted over the MEP in 18 (43%) patients. Patients with failed eradication were on average treated more intensively with antibiotics, but this may be linked to their more severe pre-MEP infection trajectories. Of the 42 patients, 26 also had sinus surgery; the majority (n=15) showed MEPs adjacent to surgery, and only five had persisting clone types. Importantly, combined phylogenetic-phenomic evaluation suggests that persisting clone types are a result of re-emergence of the same strain rather than re-infection from the environment, and similar relatedness is exhibited by paired lower and upper airway samples and in transmission cases.In conclusion, nearly half of CF patients with supposed eradication may not truly be cleared of their original bacteria according to omics-based monitoring. This distinct cohort that is persistently infected would probably benefit from tailored antibiotic therapy.
KW - Anti-Bacterial Agents/therapeutic use
KW - Cystic Fibrosis/drug therapy
KW - Humans
KW - Phylogeny
KW - Pseudomonas Infections/drug therapy
KW - Pseudomonas aeruginosa/genetics
UR - http://www.scopus.com/inward/record.url?scp=85097757915&partnerID=8YFLogxK
U2 - 10.1183/13993003.00512-2020
DO - 10.1183/13993003.00512-2020
M3 - Journal article
C2 - 33093121
SN - 0903-1936
VL - 57
JO - The European respiratory journal
JF - The European respiratory journal
IS - 4
M1 - 2000512
ER -